訂貨單號：3050044 規(guī)格: 5 ml (50 ug/ml) 根據(jù)報道，細(xì)胞培養(yǎng)過程中感染支原體的幾率是30-60%不等。經(jīng)支原體感染過后的細(xì)胞，其所有細(xì)胞生長參數(shù)，代謝皆會受到改變，近而影響到研究數(shù)據(jù)的準(zhǔn)確性。 Mycoplasma Removal Agent 功能： 1. 預(yù)防細(xì)胞培養(yǎng)過程中支原體的感染。 2. 去處感染細(xì)胞中的支原體。作用原理： MRA 是 Quinoline 類的抗生素，其抑菌機(jī)制是：抑制中支原體 DNA gyrase 的功能，使其 DNA 無法復(fù)制，而達(dá)到抑制中支原體繁殖的效果。 產(chǎn)品特點： 1. 可有效對抗多種常見中支原體菌株。 2. 作用時間快速，一星期內(nèi)立即見效。 3. Ready-to-use，只需以建議劑量加入培養(yǎng)液中即可。 4. 作用劑量底(0.5ug/ml)，低細(xì)胞毒性。樣品數(shù)據(jù)： 1. Data on mycoplasma removal effect - spontaneous infection. Duration of cultures (days) Concentration of MRA (ug/ml) 0 7 14 21 Human-derived cell-A (Human melanoma) 0.39 0.2 0.1 0 + + + + - - - + - - + + - - + + Human-derived cell-B (Human lung carcinoma) 0.78 0.39 0.2 0.1 0 + + + + + - - - + + - - - + + - - - + + + = Mycoplasma positive - = Mycoplasma negative Duration treated with MRA: 7 days 2. Efficacy comparison of MRA and pharmaceuticals on the market. MRA Tiamulin Minocycline MIC* MMC** MIC MMC MIC MMC M. orale CH-19299 M. arginini G-230 M. hyorhinis BST-7 A. laidlawii PG-8 0.05 0.1 0.05 0.0125 0.1 0.2 0.1 0.025 0.0031 0.0063 0.0031 0.05 3.13 12.5 0.39 >100 0.05 0.2 0.0031 0.05 25 >100 0.39 >100 MMC/MIC 2 128 -------------> 2048 512 -------------> 2048 M. = Mycoplasma A. = Acholeplasma * = Minimum inhibitory concentration (ug/ml) ** = Minimum mycoplasmacidal concentration (ug/ml) 3. MIC of MRA to other mycoplasma (ug/ml) Species MIC Mycoplasma fermentans PG-18 Mycoplasma salivarium PG-20 Mycoplasma hominis PG-21 Mycoplasma buccale CH-20247 0.0125 0.1 0.1 0.025 This product has been expressly manufactured by Dainippon Pharmaceutical Co., Ltd. in co-operation with MP Biomedicals, Inc.